XERS News and Press, Xeris Pharmaceuticals Inc. From 01/04/24

Company expects to be cashflow positive for the fourth quarter, report total revenue at the high end of its previous guidance of $160M-$165M, and end 2023 with over $72M in cash, cash equivalents, and short-term investments, exceeding its previous guidance of $65M-$70M Company to report Q...

2024-01-01 03:06:21 ET Summary Xeris Biopharma has shown strong revenue growth, from $2.7 million in 2019 to $152.7 million in the 12 months trailing to September 2023. The company's ready-to-use glucagon drug, Gvoke, has the potential for significant sales, especially in the US w...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will pres...

2023-12-18 17:21:05 ET Gainers: Xeris Biopharma Holdings ( XERS ) +4% . Intuitive Machines ( LUNR ) +3% . Century Aluminum Company ( CENX ) +3% . Coherus BioSciences ( CHRS ) +2% . Independent Bank ( INDB ) +2% . Losers: ...

2023-11-17 13:32:10 ET Ever wonder what signals to look for in the stock market today? Let’s talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to watch. Why Insider Buying Matters in Penny S...

--News Direct-- Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share insights on the company's focus on innovative drug formulation technology after reporting strong third-quarter results. With three growing products addressing severe hypoglycemia, Cushing's Syn...

2023-11-16 10:54:48 ET Penny stocks , usually under $5 a share, draw traders looking for big gains. But these stocks can be risky. A smart move is to watch insider trading through SEC filings. Insiders like company directors and officers have access to key info that isn’t public....

2023-11-16 10:00:07 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: XWELL, Xeris B...

2023-11-09 15:17:03 ET Xeris Biopharma Holdings, Inc. (XERS) Q3 2023 Earnings Conference Call November 9, 2023 08:30 ET Company Participants Allison Wey - Senior Vice President of Investor Relations Paul Edick - Chairman & Chief Executive Officer Steven ...

2023-11-09 07:03:05 ET More on Xeris Pharmaceuticals Xeris Biopharma Holdings: On Track To Be Cash Flow Positive Xeris Biopharma's Financial Pathway: Growth Amid Challenges Xeris Pharmaceuticals Q3 2023 Earnings Preview Xeris Biopharma tightens FY23 revenue v...